Nadmed Ltd has appointed James Lee as chief executive officer as the Finnish company scales its nicotinamide adenine dinucleotide (NAD) testing technology to meet growing global demand. Mr Lee succeeds Jari Närhi, a co-founder of Nadmed who is retiring. The new CEO has 25 years’ experience in pharmaceuticals and healthcare, with a track record of launching innovative medicines and scaling global healthcare brands.
Most recently he was chief brand officer at Pharmanovia and also held leadership roles at Novo Nordisk, where he contributed to the global launch strategy for Ozempic. Nadmed, a spin-out from the University of Helsinki, has developed tools enabling the measurement from blood of the active forms of vitamin B3, known as NAD metabolites, which play a critical role in cellular energy production and repair processes.
NADMED announced the appointment on 29 April 2026.
Copyright 2026 Evernow Publishing Ltd.